S0360090
(RS)-Selegiline hydrochloride
European Pharmacopoeia (EP) Reference Standard
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C13H17N · HCl
Numéro CAS:
Poids moléculaire :
223.74
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24
Produits recommandés
Qualité
pharmaceutical primary standard
Famille d'API
selegiline
Fabricant/nom de marque
EDQM
Application(s)
pharmaceutical (small molecule)
Format
neat
Température de stockage
2-8°C
InChI
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H
Clé InChI
IYETZZCWLLUHIJ-UHFFFAOYSA-N
Description générale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
(RS)-Selegiline hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Conditionnement
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Autres remarques
Sales restrictions may apply.
Produit(s) apparenté(s)
Réf. du produit
Description
Tarif
Faites votre choix parmi les versions les plus récentes :
Certificats d'analyse (COA)
Lot/Batch Number
Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.
Si vous avez besoin d'assistance, veuillez contacter Service Clients
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Thomas Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 120(5), 761-765 (2012-12-01)
The objective of this study is to demonstrate that application of rasagiline instead of selegiline with concomitant determination of L-amphetamine and L-methamphetamine in plasma is safe and well tolerated and influences sleep, mood, and motor behavior in patients with Parkinson's
Makoto Naoi et al.
Expert review of neurotherapeutics, 13(6), 671-684 (2013-06-07)
In Parkinson's disease, cell death of dopamine neurons in the substantia nigra progresses and neuroprotective therapy is required to halt neuronal loss. In cellular and animal models, selegiline [(-)deprenyl] and rasagiline, inhibitors of type B monoamine oxidase (MAO)-B, protect neuronal
Johanna E Kowalko et al.
Current biology : CB, 23(19), 1874-1883 (2013-09-17)
Surface populations of Astyanax mexicanus, living in rivers like their common ancestors, school, while several, independently derived cave populations of the same species have lost schooling behavior. We quantify schooling behavior in individual A. mexicanus and identify quantitative trait loci (QTL)
Tamás Tábi et al.
Expert opinion on drug metabolism & toxicology, 9(5), 629-636 (2013-03-20)
Parkinson's disease affects a growing number of people. Its major treatment, levodopa therapy, however suffers from response fluctuations in the advanced phase of the disease. Adjunctive therapies have thus gained significant importance. The selective monoamine oxidase B inhibitor, selegiline
Qing Zhao et al.
International journal of molecular medicine, 32(4), 883-891 (2013-07-24)
The monoamine oxidase type-B (MAO-B) inhibitor, selegiline, is often recommended as a first-line treatment for Parkinson's disease (PD) and has been shwon to possess neuroprotective effects. The aim of the present study was to determine whether selegiline increases the levels
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique